Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-25-094747
Filing Date
2025-09-30
Accepted
2025-09-30 07:33:24
Documents
2

Document Format Files

Seq Description Document Type Size
1 DEFA14A tm2526706d3_defa14a.htm DEFA14A 50253
2 GRAPHIC tm2526706d2_ex99-1img01.jpg GRAPHIC 6208
  Complete submission text file 0001104659-25-094747.txt   60096
Mailing Address YALELAAN 62 UTRECHT Netherlands
Business Address YALELAAN 62 UTRECHT Netherlands 31 6 3000 3035
LAVA Therapeutics NV (Filer) CIK: 0001840748 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-40241 | Film No.: 251358162
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)